Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2024-03-12 Regulatory Filings
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Rett Syndrome Patients to Receive NTI164 for 52 Weeks 2 pages 199.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 13 March 2024 from Neurotech International Limited. It announces the extension of a Phase I/II clinical trial for Rett Syndrome patients receiving NTI164 treatment for a total of 52 weeks. The content focuses on clinical trial updates, ethical committee clearance, and expected results timing. There are no financial statements, earnings data, or detailed financial analysis. The document is a corporate announcement about clinical trial progress and regulatory approval, not a financial report or earnings release. It is not a report publication announcement since it contains substantive information about the trial extension and approvals. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial progress and approvals that does not fit into other specific categories like earnings, capital updates, or management changes.
2024-03-12 English
NTI to Present at Spark Plus Conference in Singapore 24 pages 2.8MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated 13 March 2024 from Neurotech International Limited. It announces an upcoming presentation at the Spark Plus Healthcare Conference in Singapore and includes a detailed investor presentation about the company's business, strategy, clinical trials, and product development. The text explicitly states that a copy of the presentation is attached and provides extensive slides and information typical of an investor presentation. There is no indication that this is a regulatory filing, earnings release, or annual/interim report. The content focuses on company strategy, clinical development, and market positioning, which aligns with the definition of an Investor Presentation (IP). The document length (15,000 characters) and detailed content confirm it is the presentation itself, not just an announcement of a report. Therefore, the correct classification is Investor Presentation (IP).
2024-03-12 English
Notification of cessation of securities - NTI 5 pages 17.1KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the expiry of options (securities) for Neurotech International Limited. It provides specific information about securities that have ceased due to expiry, including the number of securities, reasons for cessation, and dates. The document is a formal announcement to the ASX about changes in the company's issued capital due to expiry of options. It does not contain financial statements, management discussion, or other report content. It is a regulatory announcement about securities cessation, fitting the category of Regulatory Filings (RNS) as it is a formal compliance disclosure to the exchange about securities status changes.
2024-03-11 English
Secondary Trading Notice 1 page 93.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 11 March 2024. It is titled 'Secondary Trading Notice Pursuant to Section 708A(5)(e) of the Corporations Act' and discusses the issuance of ordinary fully paid shares without disclosure under Part 6D.2 of the Corporations Act. The notice confirms compliance with relevant sections of the Corporations Act and states there is no excluded information to disclose. The document is short (2745 characters) and serves as a regulatory notice about share issuance and compliance rather than a full financial report or detailed capital update. It does not contain financial statements or detailed analysis but is a formal regulatory announcement related to capital raising compliance. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-03-10 English
Application for quotation of securities - NTI 6 pages 18.7KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) form used for the application for quotation of securities. It details the issuance and quotation of new securities resulting from options being exercised or convertible securities being converted. The document includes specifics such as the number of securities, issue date, issue price, and the class of securities. It is not a financial report, earnings release, or management discussion, but rather an official announcement related to capital changes and securities quotation on the exchange. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is a full announcement, not a brief notice or a report publication announcement.
2024-03-07 English
Notification regarding unquoted securities - NTI 5 pages 17.4KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted options (securities) by Neurotech International Limited. It includes specifics about the number of securities issued, their types, issue dates, and references to previous announcements (Appendix 3B). The content focuses on the notification of securities issuance and capital changes rather than financial results, management changes, or regulatory certifications. This matches the definition of a Share Issue/Capital Change announcement, which covers new share issues, stock splits, or other capital changes. The document is not a full financial report, earnings release, or regulatory filing, but a formal notification of capital changes.
2024-03-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.